Adenocarcinoma

Locally Advanced or Metastatic

2nd Line

HEP0074
Phase II Oral Glipizide vs
Physician's Choice in
Plexiform Growth
Factor Receptor
(EGFR)-Altered
Chemotherapy- and
EGFR Inhibitor-
Refactory /
Refractory
Cholangiocarcinoma
(FREST-308)
PI: Goyal
Sponsor: TransThera
Sciences (Worthing),
Inc.

GIO626
Phase IIb
Open-Label
Controlled Study
of CTX-300 in
Glioblastoma
Advanced, Refractory
Metastatic Malignant
Meningioma, Inoperable
Wild Type/Unknown
Tumor Type
PI: Heidel
Sponsor: CTX-300
Pharmaceuticals,
Inc.

GIO627
Bravofine-7,
Phase IIb in
Glioblastoma
Advanced, Refractory
Metastatic Malignant
Meningioma, Inoperable
Wild Type/Unknown
Tumor Type
PI: Sohn
Sponsor: Bechem
Therapeutics, Inc.

SARC03055
Phase III
Translational
Genomic
Ablation Using
Radio-Focused
Brachytherapy in
Cholangiocarcinoma
Patients in the
Liver
PI: Bedi
Sponsor: Ne-Wave
Therapeutics, Inc. (Part of J&J
Medical Devices Division)

Metastatic

1-3 Lung Nodules
Amenable to
Ablation

KEY
Pending
Open for Enrollment
Observational Study
Optional Path
Link
Total Pending
Enrollment on Hold
Extension Study
Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu